Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 206

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 206
---
 summary description of the background of the negotiations and the proposed merger and does not purport to catalogue every conversation among representatives of Aptorum Group, DiamiR Biosciences and other parties. The terms of the Merger Agreement are the result of extensive arm’s -length negotiations among Aptorum’s and DiamiR’s management and members of the Aptorum board and the DiamiR board of directors, along with Aptorum’s and DiamiR’s respective financial advisors and legal counsel. In the ordinary course of business, the Aptorum Group Board, with the assistance of senior management and advisors, regularly reviewed the near -termand long -termstrategy, positioning, and operating prospects of Aptorum Group with a view toward maximizing stockholder value. These reviews included, from time to time, discussions about a possible business combination and whether such a complementary combination could offer the best opportunity to maximize stockholder value, as well as a review of the relative potential benefits and risks associated with such action. On January 2, 2025, Aptorum Group announced that it entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares in a registered direct offering raising $3,000,000 at an offering price of $2.00 per share. DiamiR Biosciences, who’s business objectives include the development of lab -developedtests (LDTs) under Clinical Laboratory Improvement Amendments (CLIA) and FDA guidelines primarily based on the identified microRNA signatures for brain health and other conditions, and potentially the development of blood protein biomarkers for risk stratification of cognitively unimpaired individuals vs MCI vs AD patients, and which requires funding through means of equity offerings, debt financings or grants, had previously determined it was in the best interests of DiamiR and its shareholders to pursue entry into the public market through means of an initial public offering in order to enable increased funding opportunities necessary for DiamiR’s business operations. On April 2, 2025, Aptorum Group initially approached DiamiR Biosciences with the help of their legal counsel Hunter Taubman Fischer & Li. On April 16, 2025, Aptorum Group announced the receipt of a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non -compliancewith the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2). As stated within its Annual Report on Form 20 -Ffor